



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Niflumic acid (Standard)

Cat. No.:	HY-B0493R
CAS No.:	4394-00-7
Molecular Formula:	C ₁₃ H ₉ F ₃ N ₂ O ₂
Molecular Weight:	282.22
Target:	COX; Chloride Channel
Pathway:	Immunology/Inflammation; Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC₅₀ value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acid exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis^{[1][2][3][4][5][6][7][8]}.

REFERENCES

- [1]. Criddle, D.N., et al., Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. *Br J Pharmacol*, 1997. 120(5): p. 813-8.
- [2]. Jabeen, T., et al., Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. *Acta Crystallogr D Biol Crystallogr*, 2005. 61(Pt 12): p. 1579-86.
- [3]. Picollo, A., et al., Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. *J Membr Biol*, 2007. 216(2-3): p. 73-82.
- [4]. Yuliya V Kucherenko, et al. Niflumic Acid Affects Store-Operated Ca²⁺-Permeable (SOC) and Ca²⁺-Dependent K⁺ and Cl⁻ Ion Channels and Induces Apoptosis in K562 Cells. *J Membr Biol*. 2014 Jul;247(7):627-38.
- [5]. Byeong Mo Kim, et al. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARc ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. *Cancer Lett*. 2011 Jan 28;300(2):134-44.
- [6]. Shengqun Luo, et al. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. *Int J Clin Exp Pathol*
- [7]. I Florentin, et al. MODULATION OF IMMUNE RESPONSES IN MICE BY ORAL ADMINISTRATION OF NIFLUMIC ACID. *Int J Immunopharmacol*. 1989;11(2):173-83.
- [8]. Mitsuko Kondo, et al. Niflumic Acid Inhibits Goblet Cell Degranulation in a Guinea Pig Asthma Model. *Allergol Int*. 2012 Mar;61(1):133-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA